Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of solifenacin suspension in pediatric overactive bladder
NL-OMON37713Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of solifenacin in overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoint: Incidence and severity of adverse events. Started Jul 2013; status: active, not recruiting.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON37713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37713.